(BUSINESS WIRE)–Jan. 21, 2015– Illumina, Inc. (NASDAQ:ILMN) today announced the launch of the MiSeq FGx Forensic Genomics System, the first fully validated forensic next-generation sequencing (NGS) system, which simultaneously interrogates short tandem repeats (STR) and other valuable genetic markers, including single nucleotide polymorphisms (SNPs), to provide informative DNA profiles. The system enables more robust analysis of a broader range of genetic markers in a single workflow than previous technology a… Read more »
Shares of Illumina closed yesterday at $196.73 . ILMN has a 1-year high of $199.48 and a 1-year low of $127.69. The stock’s 50-day moving average is $187.34 and it’s 200-day moving average is $177.50.
On the ratings front, Illumina has been the subject of a number of recent research reports. In a report published on January 6, analyst Tycho Peterson from J.P. Morgan assigned a Buy rating to ILMN, with a price target of $270, which represents a potential upside of 37.2% from where the stock is currently trading. Separately, on November 28, Wedbush`s Zarak Khurshid maintained a Buy rating on Illumina shares and has a price target of $200.
In total, 2 research analysts have assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $196.73 which is 3.0% above where the stock closed yesterday.
Illumina, Inc., is developer, manufacturer and marketer of integrated systems for the large scale analysis of genetic variation and biological function.